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Abstract
Background: Acute malnutrition is currently divided into severe (SAM) and moderate (MAM) based on level of
wasting. SAM and MAM currently have separate treatment protocols and products, managed by separate international
agencies. For SAM, the dose of treatment is allocated by the child’s weight. A combined and simplified protocol for
SAM and MAM, with a standardised dose of ready-to-use therapeutic food (RUTF), is being trialled for non-inferior
recovery rates and may be more cost-effective than the current standard protocols for treating SAM and MAM.
Method: This is the protocol for the economic evaluation of the ComPAS trial, a cluster-randomised controlled,
non-inferiority trial that compares a novel combined protocol for treating uncomplicated acute malnutrition
compared to the current standard protocol in South Sudan and Kenya. We will calculate the total economic costs
of both protocols from a societal perspective, using accounting data, interviews and survey questionnaires. The
incremental cost of implementing the combined protocol will be estimated, and all costs and outcomes will be
presented as a cost-consequence analysis. Incremental cost-effectiveness ratio will be calculated for primary and
secondary outcome, if statistically significant.
Discussion: We hypothesise that implementing the combined protocol will be cost-effective due to streamlined
logistics at clinic level, reduced length of treatment, especially for MAM, and reduced dosages of RUTF. The findings of
this economic evaluation will be important for policymakers, especially given the hypothesised non-inferiority of the
main health outcomes. The publication of this protocol aims to improve rigour of conduct and transparency of data
collection and analysis. It is also intended to promote inclusion of economic evaluation in other nutrition intervention
studies, especially for MAM, and improve comparability with other studies.
Trial Registration: ISRCTN 30393230, date: 16/03/2017.
Keywords: Cost-effectiveness, Severe acute malnutrition, Moderate acute malnutrition, Community management
of acute malnutrition, Cost-consequence analysis
Background
Tackling undernutrition in all its forms is a major global
health priority demonstrated by its inclusion in the recent
Sustainable Development Goals [1]. Stunting, severe acute
malnutrition (SAM) and intrauterine growth restriction
together are responsible for 21% of disability-adjusted life-
years for children under 5 years [2]. Annually, acute mal-
nutrition specifically affects 52 million children aged under
5 years and is associated with a high mortality rate if un-
treated as well as multiple long-term implications [3, 4].
Acute malnutrition is currently defined as low weight-for-
height, low mid upper arm circumference (MUAC), and/or
presence of bilateral oedema. It can be either moderate
(MAM) or severe (SAM), depending on the extent of wast-
ing. SAM cases, without medical complications, are treated
through outpatient therapeutic programmes, where they
receive routine medical care and a weekly take-home
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ration of ready-to-use therapeutic food (RUTF). Although
there is currently no consensus on how best to manage
MAM cases, they are often treated in food-insecure set-
tings through supplementary feeding programmes (SFP),
where they receive bi-weekly take-home rations of ready-
to-use supplementary food [5, 6]. When discussing SAM
and MAM in combination, the term ‘global acute malnu-
trition’ (GAM) is applied.
The current system of two parallel malnutrition treat-
ment programmes and product supply chains means
that SAM programmes are often prioritised over those
for MAM, resulting in no services for MAM children in
many settings. In contexts where the treatment of both
SAM and MAM are available, the parallel systems may
be resulting in an inefficient use of resources. In
addition, current dosage of RUTF for treatment of SAM
is based on the weight of the child, requiring multiple
calculations by health workers and, in some cases, chil-
dren are provided with a higher dose and for a longer
period of time than required [7].
ComPAS (Combined Protocol for Acute Malnutrition
Study) aims to assess whether unifying and simplifying
the treatment of uncomplicated SAM and MAM for
children aged 6–59 months into one programme would
have an impact on the effectiveness of treatment. The
‘combined protocol’ will treat all SAM and MAM cases
with RUTF using a simple MUAC-based dosage proto-
col, and this will be compared to the ‘standard protocol’
in a non-inferiority, cluster-randomised controlled trial.
Further details of the ComPAS trial study design are
published elsewhere [7, 8].
Few studies have assessed the cost-effectiveness of nutrition
interventions, particularly with regard to treatment of MAM
and changes in acute malnutrition protocols. Since the intro-
duction of the current standard community-based protocol
for treatment of SAM in 2001, studies have found this model
to be cost-effective compared to the previous model of in-
patient treatment [9–11]. Treatment for SAM is estimated to
cost between USD$26 and USD$53 per disability-adjusted life
year averted [9–11], and between USD$100 and USD$203
per child treated [11, 12]. It has also been estimated that costs
can be as high as USD$500 per child treated by non-
government organisations in fragile or emergency contexts
[13]. The cost per MAM child treated is not widely published,
perhaps due to the current lack of recommended protocols.
One previous study has trialled a combined protocol,
using RUTF to treat MAM and SAM, and found it to have
a comparable recovery rate (83% vs. 79%) for GAM and
higher coverage (71% vs. 55%, P = 0.0005) than the stand-
ard protocol [14]. This clinical trial was conducted in Si-
erra Leone in 2013 and tested the efficacy of an
integrated, MUAC-only protocol for the treatment of
SAM and MAM using one product (RUTF) at different
standardised doses for children with a height < 115 mm
(175 kcal/kg/day) and 115–125 mm (75 kcal/kg/day),
against the standard protocol, which used corn-soy
blended flour (CSB++) for children with MAM. The study
also presents the cost of therapeutic food from a
programme perspective. The cost of RUTF was US$4/kg,
which was the local producer’s price in 2013, and US$1.
30/kg for CSB++ [14]. The cost of RUTF used to treat a
SAM case was US$36 in the combined protocol, com-
pared to US$68 in the standard programme. The cost of
food products to treat a case of MAM was US$12 in both
the combined and standard management arms.
Despite the higher price of RUTF compared to CSB+
+, the study found that the integrated protocol was less
costly due to the lower dose of RUTF provided to SAM
cases and faster recovery rates of children with MAM.
The authors theorised that, due to the reduced food
costs and simpler logistical requirements, it seemed
likely that the integrated management would be less
costly to implement per child treated than the standard
protocol [14]. They also found a lower proportion of
SAM in their combined protocol arm, which they
hypothesised might be due to SAM cases averted by
earlier treatment of MAM with RUTF. The need for a
more complete economic analysis of the combined
protocol was highlighted.
Our study builds on this previous work, and aims to
estimate the full economic cost of the ComPAS com-
bined protocol, compared to the standard protocol, from
a societal perspective. We hypothesise that the com-
bined protocol will be more cost-effective than the
standard protocol as overall costs will be lower and an
equivalent recovery rate from GAM will be achieved.
Many cost-effective health interventions have better
health outcomes but at a greater cost; we hypothesise
that the combined protocol will have as high recovery
rates as the standard protocol, at a lower cost (Fig. 1).
Based on the literature, we hypothesise that cost reduc-
tions will come from the streamlining of logistics and
personnel, the potential for provision of lower weekly
dosages of RUTF, and the faster recovery of children.
As few protocols have been published for economic
evaluations in child health, this article follows a call for
publication of complex economic protocols [15]. The
publication of economic protocols, such as this, aims
to improve the rigour of conduct among costing stud-
ies, improve comparability, and familiarise researchers
and programme implementers in global health nutri-
tion with the methodologies of economic evaluation
in order to encourage its inclusion in more nutrition
intervention trials.
Aims and objectives
The aim of the ComPAS economic evaluation is to
measure the cost and cost-effectiveness of a ‘combined
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protocol’ for treatment of SAM and MAM compared to
the standard protocol, which separates SAM and MAM
treatment into an outpatient therapeutic programme
and SFP. The primary marker of effectiveness will be re-
covery from GAM, defined as achieving a MUAC ≥ 125
mm. The secondary markers of effectiveness will be
programme coverage, length of treatment, treatment
adherence, average weekly weight gain and average
weekly MUAC gain.
The specific objectives of the economic evaluation
are to:
1. Quantify the economic cost of implementing the
combined protocol (intervention) and the standard
protocol (control), using a combination of activity-
based costing and ingredients approach.
2. Quantify the economic cost to households partaking
in the combined protocol and the standard protocol.
3. Estimate any incremental costs to the wider health
system by the implementation of the combined
protocol compared to the standard protocol using
programme referral data and published literature.
4. Compute the incremental cost per child recovered
for the combined protocol compared to the
standard protocol.
5. Present the costs and any significant differences in
the primary and secondary outcomes (i.e. recovery
rate, coverage, defaulting, average weight gain,
average MUAC gain and length of treatment) as a
cost-consequence analysis.
Methods
Study design
This study is a cost-consequence and cost-effectiveness
analysis of the ComPAS trial, a multi-country, cluster-
randomised, controlled trial taking place between May
2017 and July 2018. We will estimate the total costs of
both protocols from a societal perspective, including
both service provider and household costs. Data collec-
tion for the costing study will take place at the mid-
point of recruitment for the main trial, and accounting
data will be accessed at the end of the study implemen-
tation. Time horizons for the costing study are within
the trial period only.
Ethical approval for the trial was obtained from the
Kenya Medical Research Institute (KEMRI) (5/1/2017,
ref.: 551), the South Sudan Ministry of Health Internal
Review Board (21/11/2016), and the London School of
Hygiene and Tropical Medicine (28/11/2016, ref: 11826).
This protocol describes the methods specific to the
economic study alongside the ComPAS randomised
controlled trial, following the SPIRIT checklist format
(see Additional file 1); further details of the protocol
have been published elsewhere [8].
Target population
The target population for the ComPAS trial is children
aged 6–59 months who are diagnosed with uncomplicated
acute malnutrition and are eligible for outpatient treat-
ment. Acute malnutrition is defined in the trial as a MUAC
< 125 mm and/or bilateral pitting oedema only. Children
with a weight-for-height < −2 z-score will be treated, how-
ever, they will not be included in the primary analysis. The
only reason for non-inclusion will be if the child is receiv-
ing SAM or MAM treatment at another facility.
All caregivers of children presenting with acute malnu-
trition at participating health facilities, who meet the
inclusion criteria, are approached for consent to take
part in the trial. Details of the informed consent process
can be found in the trial protocol [8]. If the caretaker
chooses not to participate in the trial, their child is
enrolled for treatment only and their information is not
recorded for study purposes.
For the economic evaluation, the target populations
for the collection of resource-use data are (1) carers of
children receiving treatment for acute malnutrition as
part of the trial; (2) staff working to treat children en-
rolled in the trial; (3) support, supervision, management
and logistics staff relevant to the treatment of children
in the trial; and (4) partner organisations supporting any
aspect of care provision to children enrolled in the trial.
Setting and randomisation
The study will take place in 12 health facilities in
Nairobi County in Kenya and 12 health facilities in
Fig. 1 Depiction of hypothesised economic outcome of the ‘combined
protocol’ on the cost-effectiveness matrix. We hypothesise that the
‘combined protocol’ for treatment of severe and moderate acute
malnutrition will have as high recovery rates as the standard
treatment protocol, but at a lower cost
Lelijveld et al. Trials  (2018) 19:252 Page 3 of 9
Aweil East County, South Sudan. Six health facilities in
each country have been randomised to the control arm
and six to the intervention arm using a random
sequence generated and applied to a pre-written list of
participating clinics. Health facility staff are not blinded
to the trial, as they are required to follow the specific
protocol to which their facility is allocated.
Nairobi County is an urban area where more than 60%
of residents live in informal settlements, in which the es-
timated prevalence of wasting (GAM) is 2.8% [16]. The
2014 Kenya Demographic and Health Survey estimated
that 17% of children aged under 5 years in Nairobi were
stunted, and 4% were underweight; further 60.4% of chil-
dren were fully immunised and 93.6% of women living
in urban areas were literate [17]. The 12 health facilities
in Nairobi are operated by the Ministry of Health with
support from International Rescue Committee specific-
ally for treatment of malnutrition. These facilities were
selected as study sites by the Ministry of Health based
on the high burden of malnutrition; they are approxi-
mately 3–5 km apart.
Aweil East is a rural setting in Northern Bahr el Ghazal
State in South Sudan. Children under 5 years of age are
thought to account for 19% of the population and 76% of
the population in the State live below the poverty line
[18]. A Standardized Monitoring and Assessment of Relief
and Transitions survey conducted in Aweil East in April
2014 reported a GAM prevalence of 26% [19]. Coverage
of measles immunisations is thought to be 27%, and the
2009 National Baseline Household Survey found national
female literacy rates to be 16% [20]. The 12 health facilities
included in this study are operated by an international
non-government organisation (Action Against Hunger),
are approximately 20–30 km apart from each other and
provide malnutrition services only.
Intervention
The control arm follows the standard protocol defined
by national guidelines for the treatment of SAM and
MAM, and the intervention arm follows a combined
protocol for SAM and MAM. The RUTF dosage for the
intervention was developed based on a retrospective
analysis of acute malnutrition treatment data in order to
propose a physiologically appropriate, simplified dosage
that meets the energy requirements for acutely malnour-
ished children defined by MUAC [7]. Children treated in
the control arm receive 200 kcal/kg/day of RUTF if they
are classified as SAM (MUAC < 115 mm or bilateral pit-
ting oedema), and 500 kcal/day of ready-to-use supple-
mentary food if they are classified as MAM (MUAC 115
to < 125 mm), as per national protocols. Children treated
in the intervention arm receive 1000 kcal/day of RUTF
if they have SAM and 500 kcal/day of RUTF in they
have MAM. Further details of the two protocols can be
found in Table two of Bailey et al. [8] and in the online
trial registration (ISRCTN 30393230) [21].
Health outcomes
The primary outcome of the ComPAS trial is ‘proportion
of children recovered’; however, as a non-inferiority trial,
it is expected that this outcome will not be statistically
significantly different between intervention and control
arms. For the purposes of analysis, recovery will be
defined as two consecutive measurements with a MUAC
≥ 125 mm and no oedema for both control and interven-
tion arms.
The secondary outcomes will be treatment coverage,
defaulter rate, length of treatment, average weight gain
and average MUAC gain. Coverage is defined as propor-
tion of children eligible for treatment (MUAC < 125
mm) who receive treatment, assessed by a standardised
Semi-Quantitative Evaluation of Access and Coverage
survey [22]. Defaulting is defined as absence from treat-
ment appointments for 3 consecutive weeks. Further
details of health outcomes can be found in the trial
protocol [8]. Statistically significant secondary outcomes
will be presented in the cost-consequence analysis and
unit costs presented where appropriate, e.g. cost per unit
coverage, although the conservative a priori hypothesis
for all outcomes is non-inferiority.
Maust et al. [14] found a reduced caseload of SAM
in their version of the combined protocol and
hypothesised that this could be due to more intensive
treatment of MAM resulting in prevention of SAM.
We will also explore any adjusted differences in SAM
caseloads between the intervention and control arm
and, if a significant difference is found, the cost per
SAM case averted will be estimated. They also found
that SAM children who received the intervention re-
covered more rapidly and therefore had a reduced
cost of RUTF [14]. We will also present the cost of
RUTF per SAM case simply using the number of
sachets prescribed and the local unit cost per sachet,
in order to compare with previously published values.
Nevertheless, it is important to note that the study by
Maust et al. [14] compared their combined protocol
to routine control clinics, whereas this study will
compare a combined protocol to fully supported, ‘op-
timal’ control sites. Exploration of differences in
defaulting rates and relapse rates between the two
protocols will also be considered in relation to their
effect on total programme costs.
Recent health seeking and referrals to external medical
care will also be assessed in a sub-set of study partici-
pants in order to estimate differences in health seeking
behaviour and utilisation of wider health services, which
will inform the estimated cost of the intervention to the
wider health system.
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Sample size
There will be 12 health facilities (clusters) in South
Sudan and 12 in Kenya; in each country, six health facil-
ities will be randomly allocated as intervention and six
as control, with 150 children per clinic. The sample size
for the main trial outcome was calculated using an ex-
pected recovery rate of 85% based on the average
programme statistics for each site, allowing for a 10%
non-inferiority margin, with 80% power at the 5% level
of significance.
As the study is only statistically powered for determin-
ing effectiveness across both countries rather than
within each country, the economic evaluation will be
conducted using pooled costs and outcomes from both
sites. Pooled and site-specific costs and outcomes will
also be presented in the cost-consequence analysis.
Cost data collection will be carried out at all 24 health
facilities participating in the study. For beneficiary costs,
an exhaustive sample will be asked a simple survey
about cost and time implications of participating in the
programme as part of the main trial exit interview. In
addition, more in-depth group interviews with benefi-
ciary carers will take place with between four and six
purposively selected participants at each clinic (i.e. ~72
participants for each country) (Table 1). Interview sample
sizes will be determined by data saturation. Survey sample
sizes will be dictated by the trial sample size; however,
post-hoc sample size calculations for differences in cost
and time data will be calculated where possible.
Measuring resources and costs
The economic evaluation will be conducted from a
societal perspective, measuring programme and
household costs. A combination of activity-based cost-
ing and ingredients approach will be used to estimate
programme costs. See Table 1 for list of activities and
ingredients. The timing of data collection points can
be seen in Fig. 2. Full start-up costs will not be col-
lected as protocol development has been on-going
across previous years and previous studies; however,
simple start-up costs relevant for future use, such as
stakeholder meetings, trainings, community sensitisa-
tion and translation of resources, will be estimated.
Note that cost of inpatient treatment for SAM will
not be collected as it is not part of the intervention.
Measuring programme costs
Major activities guiding the programme costs have been
derived from other community management of acute mal-
nutrition costing analyses [9, 23], namely treatment, out-
reach, supply logistics, training, supervision and
management. The ingredients within each activity will be
quantified and costed using a clinic audit, key informant
interviews with clinic staff, Ministry of Health regional
level staff and relevant partner organisations, and account-
ing data, where available (Table 1). Capital costs will be
annualised over their expected useful life (3 years for com-
puters, 5 years for cars and other equipment, 10 years for
communal land) and discounted at a rate of 3%. The allo-
cation of joint costs will be divided by activity and by
study arm, informed by the weekly clinic survey and
study-midpoint staff time-use interview.
As programme costs are the primary area where we
anticipate the main differences to lie between interven-
tion and control, we will collect primary resource use
data for all activity areas rather than rely on assumptions
applied to accounting data. Specifically, we hypothesise
differences in therapeutic food and staff costs.
Measuring household costs
Basic travel time and costs will be measured using sur-
vey questions to all study participants during the main
trial exit interview. In Kenya, survey data will be col-
lected electronically and stored on a secure server. In
South Sudan, survey data will be collected on paper
and entered using the same electronic data collection
system as in Kenya, which includes appropriate skip
logic, value restrictions and data checks. Group inter-
views with a sub-sample of participants during their en-
rolment in the study will also be undertaken to
consider any hidden or abstract costs to households as
well as to calculate potential lost earnings due to time
spent at the programme. Participants will be purpos-
ively selected to represent both SAM and MAM chil-
dren as well as a range of travel times.
Estimating costs to the wider health system
Wider health system costs will be estimated using the
number and nature of referrals of participating children
as well as any differences in health-seeking behaviour.
Referral nature and number will be estimated based on
quarterly clinic surveys and health-seeking behaviour
will be discussed in participant group interviews. Cost
will be estimated using existing published data on costs
of treating common referrals, for instance WHO
CHOICE cost estimates [24].
Analytical methods
Incremental cost-effectiveness ratios will be calculated
for the primary outcome (i.e. incremental cost per add-
itional child recovered) and for secondary outcomes
where a statistically significant difference is found.
Potential secondary outcomes for inclusion are treat-
ment coverage, defaulter rate, length of treatment, aver-
age weight gain and average MUAC gain. Univariate and
multivariate sensitivity analyses will be performed in
order to assess the potential best case and worse case
variability in costs and outcomes. Areas of potential
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variability will be determined through exploration of the
effectiveness data and the researcher’s evaluation of cost
data uncertainty following data collection. For example,
there could be variability in costs or time-use informa-
tion provided by staff and other key informants due to
recall error.
In addition to incremental cost-effectiveness ratios, the
economic evaluation will be presented as a cost-
consequence analysis where all costs and outcomes will
be listed, including the multiple secondary trial
outcomes, allowing policymakers to compare costs with
health gains for the combined protocol.
Costs will be presented in 2017 prices in local currency
(Kenyan shillings and South Sudanese Pounds) as well as
2017 US dollars, which will allow for comparison across
the two country sites as well as comparison with other
studies. Costs and outcomes will not be discounted as the
intervention does not span more than 1 year.
Results are expected to be generalisable to multiple Afri-
can contexts, particularly within the range of the
Table 1 Outline of data categories and sources
Activity Ingredients Data sources Sample size
Programme costs
Treatmenta Therapeutic food 1. MoH/partner accounting
data
2. Clinic audit
3. KII with partners (UN agencies)
4. Time allocation questionnaire
1. N/A
2. All clinics (12 per country)
3. One from each partner
4. Purposive sample representing all types of clinic staff involved
in treatment
Human
resources
Other medical
supplies
Other supplies
Space
Outreach Transport 1. MoH/partner accounting data
2. Clinic audit
1. N/A
2. All clinics (12 per country)
Supplies
Human
resources
Supply logistics Storage 1. MoH/partner accounting data
2. KII with partners and clinic
staff
3. Time allocation questionnaire
1. N/A
2. Purposive sample representing all partners
3. Purposive sample representing all types of clinic staffTransport
Human
resources
Training Space 1. MoH/partner accounting data
2. Clinic audit
1. N/A
2. All clinics (12 per country)
Supplies
Human
resources
Supervision Transport 1. KII with supervisors 1. Purposive sample representing all supervisors
Human
resources
Management Human
resources
1. MoH/partner accounting data
2. KII with MoH/partner support
staff
3. Time allocation questionnaire
1. N/A
2. Purposive sample
3. All support staff involved in the programme
Equipment
Space
Household costs
Participating in treatment Supplies 1. GIs with beneficiaries
2. Beneficiary exit survey
1. 4–6 randomly selected beneficiaries from each clinic
2. All beneficiaries
Time
Transport
Wider health system costs
Referral to other healthcare
providers
Space 1. Clinic audit
2. Literature estimates
1. All clinics (12 per country)
2. N/A
Human
resources
Supplies
aNote that this does not include SAM inpatient treatment
KII key informant interview, MoH Ministry of Health, GIs group interviews, N/A not applicable
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sensitivity analyses. Household food security estimates for
each site will aid identification of where results may be
generalisable to (i.e. food insecure settings). In addition, as
treatment in one study site is government-led and in the
other it is partner-led, results from each should be of
interest to implementers with a variety of programme
structures. One limitation of the study is that the main
analysis will present an average of the two sites, therefore
masking some of the heterogeneity between sites.
Anonymised hardcopies of data will be stored in ap-
proved, secured locations in the respective countries;
anonymised electronic data for the economic evaluation
will be stored on a secure server in the UK, assessable
only by the research team. No participant identifiable
data will be recorded. Results will be reported following
the consolidated health economic evaluation reporting
standards (CHEERS) checklist [25].
Discussion
This economic evaluation will provide key information
for policymakers when considering alterations to the
GAM treatment protocols. As a non-inferiority trial, the
recovery rates are expected to be statistically similar
between each protocol, hence the comparative cost-
effectiveness will likely play a larger role in policy
decision-making.
With regard to limitations, this study will not be able
to assess the cost impact of the combined protocol on
international logistics and supply chain, which may be
further streamlined if the combined protocol were to be
scaled-up. In addition, the full extent of the hypothesised
cost savings of the combined protocol is unlikely to be
realised during the period of this study (8–10 months).
A longer time horizon is necessary to reveal the impact
of an improved treatment protocol on the reduction in
acute malnutrition caseload through prevention of
deterioration from MAM to SAM. Finally, as is the case
with many controlled trials, the extra support offered to
both the combined and standard protocols will likely
result in higher costs, which should be noted when gen-
eralising the results to routine programmes.
This publication aims to improve rigour in conduct
and transparency of data collection and analysis. The
publication of this protocol also intends to promote
Baseline Admission
visit
Follow-up 
visits
Discharge
visit
4-month 
post-
discharge 
visit
Health facility 
informed consent x
Randomization of 
clusters
x
Eligibility screen
x
Individual 
Informed consent x
Demographic data
x
Nutritional and 
medical 
assessment x x x x
Cost questionnaire x
ASSESSMENTS Start of study
Mid-Study End of 
study
Costing interviews x
Mid-term safety 
review
x
SQUEAC coverage 
assessments x
Costing 
accounting data x
Adverse event 
monitoring x x x x
Fig. 2 Schedule of enrolment, interventions and assessments
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inclusion of economic evaluation in other nutrition inter-
vention studies, particularly for MAM, and improve com-
parability with other studies. Regardless of whether the
new protocol is more cost-effective than the standard
protocol or not, the evidence provided by this evaluation
will contribute significantly to the currently limited evi-
dence regarding cost-effectiveness of nutrition-specific
interventions.
Trial status
This is protocol version number 1, finalised on 01/06/2017.
Recruitment of trial participants began on 15/05/2017 and
is expected to be completed on 01/06/2018, at which point
accounting data and survey data will be analysed. Inter-
views for the economic evaluation began on 20/06/2017
and will be completed on 20/12/2018.
Additional files
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOC 132 kb)
Additional file 2: Caretaker consent form for group interviews (Kenya).
(DOCX 26 kb)
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